Welcome to our dedicated page for Arcus Biosciences SEC filings (Ticker: RCUS), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Arcus Biosciences, Inc. filings document the regulatory record of a clinical-stage biopharmaceutical company whose common stock trades on the New York Stock Exchange under RCUS. Form 8-K reports include quarterly and annual results furnished with pipeline updates, clinical program disclosures, collaboration updates, executive changes and material agreements tied to the company’s financing and development activities.
Arcus filings also cover capital structure and governance matters, including a completed common stock offering, amendments to a loan and security agreement, annual proxy materials, board and executive compensation disclosures, equity incentive matters and stockholder meeting proposals. The filing record reflects risk and operating disclosures connected to drug development, clinical studies, regulatory pathways, collaborations and funding needs.
Arcus Biosciences Chief Accounting Officer reports option exercise and share sale. On 11/26/2025, the officer exercised a stock option to acquire 1,900 shares of Arcus Biosciences common stock at $13.33 per share and on the same date sold 1,900 shares at $26 per share under a Rule 10b5-1 trading plan. After these transactions, the officer directly beneficially owned 27,363 shares of common stock and 9,500 stock options with a $13.33 exercise price, which are scheduled to become exercisable in 48 equal monthly installments after January 1, 2025 and expire on January 22, 2035.
Arcus Biosciences (RCUS) Chief Financial Officer reports stock sale under pre-arranged plan. The CFO sold 5,000 shares of Arcus Biosciences common stock on 11/26/2025 at a price of $25 per share in an open market sale coded as an "S" transaction. After this sale, the reporting person beneficially owns 87,138 shares of Arcus Biosciences common stock in direct ownership. The filing states that the sale was made under a Rule 10b5-1 trading plan, which is a pre-established program intended to allow insiders to sell shares according to set instructions.
Arcus Biosciences, Inc. (RCUS) reported insider stock sales by its President, who is an officer of the company. On November 17, 2025, a trust associated with the reporting person sold 37,114 shares of common stock at a weighted average price of $20.2274, and a further 7,836 shares at a weighted average price of $20.713. On November 18, 2025, the trust sold an additional 5,050 shares at a weighted average price of $19.75. The filing states these transactions were executed under a Rule 10b5-1 trading plan adopted on August 8, 2025. After these sales, the reporting person beneficially owned 1,037,060 shares indirectly through a trust and 367,220 shares directly.
Arcus Biosciences (RCUS) insider holders filed a notice to sell 50,000 shares of Class A common stock through Goldman Sachs & Co. LLC on the NYSE, with an indicated aggregate market value of $999,500. The filing states that 120,801,086 shares of this class were outstanding at the time referenced, providing context for the planned sale size. The shares were originally acquired from the issuer in private transactions in May 2015. Over the past three months, the same trust has already sold additional Class A shares in several transactions, including 77,167 shares on 10/29/2025 for gross proceeds of $1,617,034.48. The signer represents that they are not aware of undisclosed material adverse information about the company.
Arcus Biosciences (RCUS): Point72 Asset Management, Point72 Capital Advisors, and Steven A. Cohen filed an amended Schedule 13G reporting beneficial ownership of 4,332,479 Arcus common shares, equal to 4.1% of the class as of September 30, 2025.
The reporting persons have 0 shares with sole voting or dispositive power and 4,332,479 shares with shared voting and shared dispositive power. They certified the holdings were not acquired with the purpose or effect of changing or influencing control.
Arcus Biosciences (RCUS) reported an insider transaction by its Chief Operating Officer. On 11/07/2025, the officer exercised 50,291 stock options at $1.2276 per share and sold 50,291 common shares at a $18.9709 weighted average price under a Rule 10b5-1 trading plan. After these trades, the officer directly held 214,232 common shares. The filing notes the sales occurred across multiple trades between $18.59 and $19.42. Remaining derivative holdings include 80,583 stock options with an expiration date of 03/14/2027.
Gilead Sciences filed Amendment No. 6 to its Schedule 13D on Arcus Biosciences, updating its beneficial ownership and voting power disclosures. Gilead reports beneficial ownership of 31,424,760 shares of Arcus common stock, representing 25.6% of the class. Gilead has sole voting and dispositive power over the same 31,424,760 shares and no shared power.
The percentage is based on 122,856,086 shares outstanding as reported in a prospectus supplement dated October 31, 2025. The filing details prior purchases under multiple purchase agreements and offerings. It also notes that Jeffrey A. Bluestone holds options exercisable within 60 days for 10,750 shares, equating to 0.01% on an as‑converted basis.
Arcus Biosciences (RCUS): The company’s President reported an open‑market sale of 4,314 shares of common stock on 10/30/2025 at a weighted average price of $20.3175, executed under a Rule 10b5‑1 trading plan adopted on August 12, 2024.
Following the transaction, the reporting person beneficially owned 1,087,060 shares indirectly (by trust) and 367,220 shares directly. The price reflected multiple trades between $20.12 and $20.63.
Arcus Biosciences (RCUS) completed an underwritten public offering of common stock. The company sold 15,755,000 shares, including the full exercise of the underwriters’ 2,055,000-share option, and received net proceeds of approximately $269.7 million after discounts and expenses.
The shares were offered at a public price of $18.25 per share, with underwriters purchasing at $17.155 per share. The transaction was conducted under an effective Form S-3 registration, with Leerink Partners LLC and Goldman Sachs & Co. LLC acting as representatives of the underwriters. The offering closed on November 3, 2025.
Arcus Biosciences (RCUS) launched a primary offering of 13,700,000 shares of common stock at $18.25 per share. The transaction is expected to generate gross proceeds of $250,025,000, less underwriting discounts of $15,001,500, for proceeds to the company before expenses of $235,023,500. Arcus also granted the underwriters a 30‑day option to purchase up to 2,055,000 additional shares.
Arcus estimates net proceeds of approximately $234.5 million (or approximately $269.7 million if the option is exercised in full). The company plans to use the funds to advance R&D, including expansion of the casdatifan program and development of immunology and inflammation candidates, and for general corporate purposes. Based on 107,101,086 shares outstanding as of September 30, 2025, new investors would face an immediate dilution of $12.70 per share at the offering price. A 60‑day lock‑up applies to the company and insiders, subject to customary exceptions. The shares are expected to be delivered on or about November 3, 2025.